
To investigate the efficacy of zzso as a zzso zzso for patients receiving zzso zzso to the upper abdomen in a zzso controlled zzso 

One hundred zzso patients planned to receive zzso zzso to fields involving the upper abdomen zzso total dose, 20 zzso minimum number of zzso five) were zzso to receive zzso zzso (2 zzso orally three times a day zzso starting in the morning of first treatment and continuing until after their fifth zzso or zzso The primary end point of the study was the proportion of patients free from zzso during the study zzso Secondary end points included a zzso assessment using the core questionnaire of the European Organization for Research and Treatment of Cancer and side effects of zzso therapy in this population of zzso 

zzso zzso out of 75 patients receiving zzso had complete protection versus 37 zzso out of 75 patients on zzso zzso zzso zzso Most zzso episodes occurred during the initial phase of zzso Although there was no difference in global quality of life between the two sets of patients, patients receiving zzso had less zzso and vomiting and less loss of appetite but more zzso 

zzso 2 zzso zzso seems to be an effective zzso zzso in this zzso Side effects were acceptable, but there seemed to be no overall effect on global quality of zzso 

